Bupropion er
Pro Research Analysisby 
Searched over 200M research papers for "bupropion er"
Bupropion ER: Pharmacokinetics, Efficacy, and Safety
Pharmacokinetics of Bupropion ER
Bupropion hydrochloride is available in three formulations: immediate release (IR), sustained release (SR), and extended release (ER). A study comparing these formulations found that the ER formulation has a relative bioavailability of 72.3-78.8% compared to the IR 75 mg formulation. The study also indicated that the different release kinetics of these formulations did not alter the ratio of metabolites to the parent drug, suggesting that the differing bioequivalence results between the 150 mg and 300 mg ER tablets were not due to metabolic saturation in the gastrointestinal lumen .
Efficacy in Obesity Management
Bupropion ER, particularly in combination with naltrexone ER, has been shown to be effective in managing obesity. Clinical trials have demonstrated that naltrexone ER/bupropion ER significantly reduces body weight and improves cardiometabolic risk factors in obese or overweight adults with at least one weight-related comorbidity. The combination therapy was generally well tolerated, with nausea being the most common adverse event Greig2015Greig2015.
Cardiovascular Safety
A systematic literature review assessed the cardiovascular safety of naltrexone/bupropion ER. The review included 70 studies and found no increased risk of major adverse cardiovascular events (MACE) among users of naltrexone/bupropion ER, naltrexone with bupropion, or bupropion alone compared to non-users. The difference in proportions of MACE between treated patients and comparators did not exceed 2.5% .
Seizure Risk
While bupropion has a known history of inducing seizures, particularly in its immediate and sustained-release forms, there is limited data on the ER formulation. A case report documented a grand mal seizure in a patient six months after starting bupropion ER, highlighting the need for caution and monitoring in patients with a history of seizures or those on multiple medications .
Use in Smoking Cessation
Bupropion SR is also used as an aid for smoking cessation. Clinical trials have shown that bupropion SR significantly increases smoking abstinence rates compared to placebo and is more effective than nicotine patches. The combination of bupropion and nicotine patches provided slightly higher abstinence rates than bupropion alone, although the differences were not statistically significant. Bupropion was generally well tolerated, with insomnia and dry mouth being the most common adverse events .
Conclusion
Bupropion ER is a versatile medication with applications in obesity management, smoking cessation, and potentially other areas. Its pharmacokinetic profile ensures consistent drug release, and it has been shown to be effective and generally well tolerated. However, caution is advised due to the potential risk of seizures, and ongoing monitoring of cardiovascular safety is essential.
Sources and full results
Most relevant research papers on this topic